Evidence map›Paper›PMID 24794531›Full record

ArticleCellular signalling2014

Early NADPH oxidase-2 activation is crucial in phenylephrine-induced hypertrophy of H9c2 cells.

Nynke E Hahn, René J P Musters, Jan M Fritz, Patrick J Pagano, Alexander B A Vonk, Walter J Paulus, Albert C van Rossum, Christof Meischl, Hans W M Niessen, Paul A J Krijnen

Open access · greenAbstract read
In one paragraph

Article in Cellular signalling, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. NOX Family: Regulators of Reactive Oxygen Species Balance in Tumor Cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Nynke E HahnDepartment of Pathology, VU University Medical Center, Amsterdam, The Netherlands; ICaR-VU, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.
René J P MustersDepartment of Physiology, VU University Medical Center, Amsterdam, The Netherlands; ICaR-VU, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.
Jan M FritzDepartment of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
Patrick J PaganoDepartment of Pharmacology and Chemical Biology, Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Alexander B A VonkDepartment of Cardiac Surgery, VU University Medical Center, Amsterdam, The Netherlands; ICaR-VU, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.
Walter J PaulusDepartment of Physiology, VU University Medical Center, Amsterdam, The Netherlands; ICaR-VU, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.
Albert C van RossumDepartment of Cardiology, VU University Medical Center, Amsterdam, The Netherlands; ICaR-VU, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.
Christof MeischlDepartment of Pathology, VU University Medical Center, Amsterdam, The Netherlands; ICaR-VU, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.
Hans W M NiessenDepartment of Pathology, VU University Medical Center, Amsterdam, The Netherlands; Department of Cardiac Surgery, VU University Medical Center, Amsterdam, The Netherlands; ICaR-VU, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.
Paul A J KrijnenDepartment of Pathology, VU University Medical Center, Amsterdam, The Netherlands; ICaR-VU, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: paj.krijnen@vumc.nl.
Amsterdam UMC Location VUmc · NLAmsterdam University Medical Centers · NLUniversity of Pittsburgh · US

Funding

Reactive Oxygen Species in Vascular DiseaseR01HL079207 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PAGANO, PATRICK J · 2007 to 2018
$3.4M
TSP-1 and ROS: CD47 and SIRP-alpha as Mediators of Vascular DysfunctionR01HL112914 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ISENBERG, JEFFREY S, PAGANO, PATRICK J · 2013 to 2016
$1.7M
NHLBI NIH HHS R01 HL079207NHLBI NIH HHS R01 HL112914
6 · The paper itself

Abstract

Reactive oxygen species (ROS) produced by different NADPH oxidases (NOX) play a role in cardiomyocyte hypertrophy induced by different stimuli, such as angiotensin II and pressure overload. However, the role of the specific NOX isoforms in phenylephrine (PE)-induced cardiomyocyte hypertrophy is unknown. Therefore we aimed to determine the involvement of the NOX isoforms NOX1, NOX2 and NOX4 in PE-induced cardiomyocyte hypertrophy. Hereto rat neonatal cardiomyoblasts (H9c2 cells) were incubated with 100 μM PE to induce hypertrophy after 24 and 48h as determined via cell and nuclear size measurements using digital imaging microscopy, electron microscopy and an automated cell counter. Digital-imaging microscopy further revealed that in contrast to NOX1 and NOX4, NOX2 expression increased significantly up to 4h after PE stimulation, coinciding and co-localizing with ROS production in the cytoplasm as well as the nucleus. Furthermore, inhibition of NOX-mediated ROS production with apocynin, diphenylene iodonium (DPI) or NOX2 docking sequence (Nox2ds)-tat peptide during these first 4h of PE stimulation significantly inhibited PE-induced hypertrophy of H9c2 cells, both after 24 and 48h of PE stimulation. These data show that early NOX2-mediated ROS production is crucial in PE-induced hypertrophy of H9c2 cells.

Indexed as

AcetophenonesAnimalsCell LineEnzyme ActivationHypertrophyMembrane GlycoproteinsNADH, NADPH OxidoreductasesNADPH Oxidase 1NADPH Oxidase 2NADPH Oxidase 4NADPH OxidasesOnium CompoundsPhenylephrineRatsReactive Oxygen SpeciesAcetophenonesacetovanilloneCybb protein, ratdiphenyleneiodoniumMembrane GlycoproteinsNADH, NADPH OxidoreductasesNADPH Oxidase 1NADPH Oxidase 2NADPH Oxidase 4NADPH OxidasesNOX1 protein, ratNox4 protein, ratOnium CompoundsPhenylephrineReactive Oxygen SpeciesCardiomyocyte hypertrophyNADPH oxidaseNOX2Phenylephrine

Identifiers

PMID24794531
PMCPMC4406486
OpenAlexW1976238822

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.